Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI ...

Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.

As a result, healthcare professionals may prescribe another GLP-1 medication that works in a similar way to encourage weight loss. Although all Zepbound doses are currently available, individual ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Wegovy: FDA-approved for the management of obesity in June 2021, this medication has gained widespread attention for its effectiveness in supporting weight loss. Zepbound: Recently FDA-approved in ...